NO20084363L - 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister - Google Patents

2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister

Info

Publication number
NO20084363L
NO20084363L NO20084363A NO20084363A NO20084363L NO 20084363 L NO20084363 L NO 20084363L NO 20084363 A NO20084363 A NO 20084363A NO 20084363 A NO20084363 A NO 20084363A NO 20084363 L NO20084363 L NO 20084363L
Authority
NO
Norway
Prior art keywords
benzylphthalazine
histamine
antagonists
derivatives
substituted
Prior art date
Application number
NO20084363A
Other languages
English (en)
Norwegian (no)
Inventor
Paul Martin Gore
Simon Tennby Hodgson
Panayiotis Alexandrou Procopiou
Ashley Paul Hancock
Leanda Jane Kindon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607839A external-priority patent/GB0607839D0/en
Priority claimed from GB0706176A external-priority patent/GB0706176D0/en
Priority claimed from GB0706160A external-priority patent/GB0706160D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20084363L publication Critical patent/NO20084363L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20084363A 2006-04-20 2008-10-17 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister NO20084363L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0607839A GB0607839D0 (en) 2006-04-20 2006-04-20 Compounds
GB0706176A GB0706176D0 (en) 2007-03-29 2007-03-29 Compounds
GB0706160A GB0706160D0 (en) 2007-03-29 2007-03-29 Compounds
PCT/EP2007/053773 WO2007122156A1 (en) 2006-04-20 2007-04-18 2-substituted 4-benzylphthalazinone derivatives as histamine h1 and h3 antagonists

Publications (1)

Publication Number Publication Date
NO20084363L true NO20084363L (no) 2008-11-17

Family

ID=38226516

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084363A NO20084363L (no) 2006-04-20 2008-10-17 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister

Country Status (19)

Country Link
US (2) US20080039444A1 (es)
EP (1) EP2007735B1 (es)
JP (1) JP4489143B2 (es)
KR (1) KR20090007604A (es)
AR (1) AR060535A1 (es)
AT (1) ATE486063T1 (es)
AU (1) AU2007242842A1 (es)
BR (1) BRPI0710156A2 (es)
CA (1) CA2649029A1 (es)
CO (1) CO6140030A2 (es)
CR (1) CR10356A (es)
DE (1) DE602007010118D1 (es)
EA (1) EA200801996A1 (es)
MA (1) MA30405B1 (es)
MX (1) MX2008013406A (es)
NO (1) NO20084363L (es)
PE (1) PE20080360A1 (es)
TW (1) TW200811116A (es)
WO (1) WO2007122156A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
US20100184770A1 (en) * 2006-12-20 2010-07-22 Glaxo Group Limited Compounds
PE20091089A1 (es) * 2007-10-16 2009-08-24 Glaxo Group Ltd Composiciones farmaceuticas que comprenden 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona y furoato de fluticasona
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
GB0811447D0 (en) * 2008-06-20 2008-07-30 Glaxo Group Ltd Formulations
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US20120157446A1 (en) * 2009-06-29 2012-06-21 Glaxo Group Limited Medical use
EP2571868B1 (en) 2010-05-19 2016-05-04 Sandoz AG Preparation of posaconazole intermediates
WO2011144655A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral hydrazides
EP2571869B1 (en) * 2010-05-19 2015-09-23 Sandoz AG Purification of posaconazole and posaconazole intermediates
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
CN108329303A (zh) 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
EP4346815A1 (en) * 2021-05-27 2024-04-10 Schrödinger, Inc. Heterocyclic compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH572914A5 (es) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
EP0174464B1 (de) * 1984-09-14 1990-01-03 ASTA Pharma AG Substituierte Benzylphthalazinon-Derivate
EP0222191B1 (de) * 1985-11-11 1991-01-30 ASTA Pharma AG 4-Benzyl-1-(2H)-phthalazinon-Derivate
EP0289939A1 (de) * 1987-05-08 1988-11-09 ASTA Pharma AG Neue 4-Benzyl-1-(2H)-phthalazinon-Derivate mit einem Aminosäurerest
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
DE69912379T2 (de) * 1998-08-14 2004-05-06 Pfizer Inc. Antithrombosemittel
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
CN1787818A (zh) * 2003-03-18 2006-06-14 麦克公司 趋化因子受体活性的氨基环丁基酰胺调节剂
EP1642898B1 (en) * 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative

Also Published As

Publication number Publication date
CO6140030A2 (es) 2010-03-19
CA2649029A1 (en) 2007-11-01
AR060535A1 (es) 2008-06-25
WO2007122156A9 (en) 2008-01-24
EA200801996A1 (ru) 2009-04-28
AU2007242842A1 (en) 2007-11-01
TW200811116A (en) 2008-03-01
DE602007010118D1 (de) 2010-12-09
US20080039444A1 (en) 2008-02-14
US20090105225A1 (en) 2009-04-23
BRPI0710156A2 (pt) 2012-06-05
PE20080360A1 (es) 2008-05-22
JP2009534351A (ja) 2009-09-24
MX2008013406A (es) 2008-11-04
JP4489143B2 (ja) 2010-06-23
CR10356A (es) 2008-11-26
WO2007122156A1 (en) 2007-11-01
ATE486063T1 (de) 2010-11-15
EP2007735A1 (en) 2008-12-31
KR20090007604A (ko) 2009-01-19
MA30405B1 (fr) 2009-05-04
EP2007735B1 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
NO20082496L (no) Pyrazinderivater
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NO20084005L (no) Aminderivater
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
NO20083919L (no) Pyridin- og pyrimidinderivater som mGluR2-antagonister
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
NO20092342L (no) Azaspiroderivativater
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
EA201100503A1 (ru) Глюкозидные производные и их применения
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20071521L (no) Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application